Teratogens

Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma

Retrieved on: 
Tuesday, August 3, 2021
Drugs, Anthracyclines, Health, Doxorubicin, Teratogens, Dose

The Company anticipates dosing the first patient in the trial in the fourth quarter of this year.

Key Points: 
  • The Company anticipates dosing the first patient in the trial in the fourth quarter of this year.
  • We eagerly await reaching each higher dose level in this trial, said Andrew Mazar, PhD, Monopars Chief Scientific Officer.
  • Camsirubicin is a novel analog of doxorubicin, and doxorubicin is known to work through a dose-dependent mechanism, where higher quantities yield more anti-cancer effect.
  • If successful in ASTS, there are 13 other potential cancer indications for camsirubicin where doxorubicin is already FDA-approved, said Chandler Robinson, MD, Monopars Chief Executive Officer.

Free Webinar to Address Effects of Prenatal Exposures on Development & Behavior

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Health, Teratogens, Biology, Embryology, Midwifery, Developmental psychology, Fertility, Prenatal development, Fetal alcohol spectrum disorder, Child development, Developmental toxicity

Her expertise is in the developmental and behavioral effects of prenatal exposure to drugs and alcohol and the interaction of these effects with the postnatal environment.

Key Points: 
  • Her expertise is in the developmental and behavioral effects of prenatal exposure to drugs and alcohol and the interaction of these effects with the postnatal environment.
  • She was among the first to describe the behavioral effects of prenatal alcohol exposure and to investigate the effects of cocaine exposure on child development.
  • WHAT: "Challenges in Identifying Effects of Prenatal Exposure on Development and Behavior," a free webinar in partnership with the National Society of Genetic Counselors.
  • Be able to critique media reports and journal articles on effects of prenatal exposures.

Global Legal Cocaine Market Report 2021-2025 - Growing Demand for Pharmaceutical-grade Cocaine and Rising Number of Countries Decriminalizing and Legalizing Cocaine - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Legal, Professional services, Psychoactive drugs, Drugs, Branches of biology, Anorectics, Cocaine, Stimulants, Teratogens, Coca

The "Global Legal Cocaine Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The publisher has been monitoring the legal cocaine market and it is poised to grow by 2.47 thousand oz during 2021-2025, progressing at a CAGR of almost 4%
    The market is driven by the growing demand for pharmaceutical-grade cocaine and the rising number of countries decriminalizing and legalizing cocaine.
  • The report on the legal cocaine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
  • This study identifies the growth in the trade of legal cocaine as one of the prime reasons driving the legal cocaine market growth during the next few years.

Neutrogena Beach Defense and Ultra Sheer aerosol spray sunscreens recalled due to elevated benzene levels

Retrieved on: 
Saturday, July 17, 2021
Chemical compounds, Chemical substances, Chemistry, Benzene, Mutagens, Soil contamination, Teratogens, Sunscreen, Johnson & Johnson

Product: Neutrogena Beach Defense and Ultra Sheer sunscreens, for adults and children, in aerosol spray format.

Key Points: 
  • Product: Neutrogena Beach Defense and Ultra Sheer sunscreens, for adults and children, in aerosol spray format.
  • Issue: Johnson & Johnson Inc. is recalling all lots of Beach Defense and Ultra Sheer aerosol spray sunscreens due to elevated levels of benzene, which may pose serious health risks after long-term, repeated use.
  • Johnson & Johnson Inc. is recalling all lots of Neutrogena Beach Defense and Ultra Sheer children and adult sunscreens, in aerosol spray format, after testing conducted by the company detected elevated levels of benzene.
  • Frequent and long-term exposure (e.g., through the skin and by inhalation) to elevated levels of benzene may pose serious health risks.

Los Angeles Says: Too Much Alcohol on These Streets!

Retrieved on: 
Wednesday, July 7, 2021
Psychoactive drugs, Neurochemistry, Branches of biology, Alcohol, Teratogens, Alcohol powder, Alcohol and health

Our communities are recovering from the most severe health crisis of our time, expansion of alcohol consumption should not be our priority.

Key Points: 
  • Our communities are recovering from the most severe health crisis of our time, expansion of alcohol consumption should not be our priority.
  • Problems from excessive alcohol consumption annually cost approximately $940 for every resident, or $2.44 for every drink.
  • There are already numerous methods for consumers to acquire alcohol in person at retail outlets or through delivery from retailers.
  • The California Alcohol Policy Alliance (CAPA) unites diverse organizations and communities in California to protect health and safety, and prevent alcohol-related harm through statewide action.

22nd Century Group Provides Business Update from CEO Detailing Company Progress Over Past Year and Future Initiatives

Retrieved on: 
Friday, June 25, 2021
Psychoactive drugs, Nicotinic agonists, Alkaloids found in Erythroxylum coca, Anorectics, Anxiolytics, Nicotine, Teratogens, Tobacco, True

It has now been just over one year since I was appointed CEO of 22nd Century Group, and I would like to thank you for your enthusiasm and support of our Company.

Key Points: 
  • It has now been just over one year since I was appointed CEO of 22nd Century Group, and I would like to thank you for your enthusiasm and support of our Company.
  • Shares of 22nd Century have soared over 470% in the past 12 months.
  • The new technology provides 22nd Century with a rapid pathway to introduce reduced nicotine traits into virtually all varieties of tobacco.
  • 22nd Century has reached a true inflection point in our business -- and the best is yet to come.

Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®

Retrieved on: 
Wednesday, June 23, 2021
Cancer, Clinical medicine, Medicine, Antineoplastic drugs, Anthracyclines, Doxorubicin, Teratogens, Bladder cancer, Immunotherapy, Chemotherapy

LAWRENCEVILLE, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces that its new wholly owned subsidiary, Celsion GmbH, will manage all current and future investigator-sponsored development of ThermoDox, the Companys proprietary heat-activated liposomal encapsulation of doxorubicin.

Key Points: 
  • LAWRENCEVILLE, N.J., June 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, announces that its new wholly owned subsidiary, Celsion GmbH, will manage all current and future investigator-sponsored development of ThermoDox, the Companys proprietary heat-activated liposomal encapsulation of doxorubicin.
  • A clinical project at the National Institutes of Health to evaluate ThermoDox plus the chemotherapy drug mitomycin in bladder cancer.
  • Celsion GmbHs long-term objective is to seek partnerships that will maximize the potential of ThermoDox, ultimately providing value to the parent company.
  • Celsion also has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies.

KIYATEC Clinical Study Data Shows Test Accurately Predicts Brain Cancer Patient Response to Standard Drug Therapy Prior to Treatment

Retrieved on: 
Thursday, June 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Health, Medicine, Oncology, Cancer treatments, Lactams, Prodrugs, Temozolomide, Teratogens, Ovarian cancer, Neuro-Oncology, Clinical trial

The results, the interim data analysis of the companys 3D-PREDICT clinical study , were published June 16, 2021 in Neuro-Oncology Advances 1, an open access clinical journal.

Key Points: 
  • The results, the interim data analysis of the companys 3D-PREDICT clinical study , were published June 16, 2021 in Neuro-Oncology Advances 1, an open access clinical journal.
  • The 3D-PREDICT study met this goal early, at its interim data analysis, an achievement that is uncommon for innovations in oncology.
  • KIYATECs test results accurately identified the patients as future temozolomide responders or future non-responders prior to the initiation of drug treatment.
  • In newly diagnosed ovarian cancer patients, KIYATECs test prospectively and accurately predicted response to first-line chemotherapy with 89% accuracy.

IN8bio Completes Treatment of First Cohort in Phase 1 Clinical Trial with Gamma Delta T-Cell Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme

Retrieved on: 
Monday, June 7, 2021
Health sciences, Life sciences, Branches of biology, Drug discovery, Biotechnology, Cancer treatments, Cell biology, Temozolomide, Teratogens, DSMB, Clinical trial, Cell therapy

INB-200 was co-administered to patients undergoing the standard-of-care therapy for GBM during the temozolomide (TMZ) maintenance treatment.

Key Points: 
  • INB-200 was co-administered to patients undergoing the standard-of-care therapy for GBM during the temozolomide (TMZ) maintenance treatment.
  • The Phase 1 clinical trial of INB-200 ( NCT04165941 ) is the first-in-human trial of a genetically modified gamma delta T-cell therapy.
  • The clinical program also cleared a data safety monitoring board (DSMB) review earlier in 2021 and enrollment for cohort 2 has been initiated.
  • Gamma delta T-cells are collected from the patient, expanded, activated and genetically modified with a proprietary process developed at IN8bio.

Hims & Hers Now Offering a Dual-Action Topical Hair Loss Treatment for Men

Retrieved on: 
Wednesday, June 2, 2021
Technology, MEN, General Health, Fitness & Nutrition, Consumer, Other Retail, Alternative medicine, Health, Specialty, Cosmetics, Retail, Other Health, Internet, Other Consumer, Women, Pharmaceutical, Online Retail, Organ systems, Hair diseases, Human hair, Hair removal, Finasteride, Teratogens, Minoxidil, Hair loss, Pattern hair loss, Hims & Hers Health, Scalp reduction

The Topical Finasteride & Minoxidil Spray is a pill-free prescription alternative to traditional oral finasteride treatment that provides effective support for male pattern hair loss.

Key Points: 
  • The Topical Finasteride & Minoxidil Spray is a pill-free prescription alternative to traditional oral finasteride treatment that provides effective support for male pattern hair loss.
  • The latest in a long list of high quality personalized wellness treatments available through the Hims & Hers telehealth platform, the combination of ingredients is specifically formulated to stop hair loss and regrow hair.
  • With the addition of prescription Topical Finasteride & Minoxidil Spray, Hims is a leader in providing customizable offerings for hair loss in men, said Hims & Hers Chief Medical Officer Dr. Patrick Carroll.
  • Hims suite of hair loss products can provide a high level of personalization for men who are seeking the optimal treatment for their own hair loss journey.